AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01468337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Description: Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes).
Study NCT04469595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iluvien 0.19 MG Drug Implant
Description: 0.19 mg Fluocinolone Acetonide Intravitreal Implant
Study NCT04469595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Study NCT02763930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Study NCT02763930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk diet
Study NCT02763930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GABA-rich cheese diet
Study NCT02042157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bidet use
Description: Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
Study NCT02042157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular toileting
Description: Patients in the control arm will toilet as usual.
Study NCT03673969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Surgical method of gastric bypass
Study NCT01077297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezosentan
Description: single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
Study NCT04570839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
Study NCT04036695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ insertable cardiac monitoring system
Description: A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
Study NCT03305965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
Study NCT02074241 — intervention group
Intervention type: OTHER
Intervention: Expression analysis
Description: Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
Study NCT01067105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide HFA 160 μg
Description: ciclesonide HFA 160 μg once daily
Study NCT02036073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
Study NCT00454337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF + EFV or LPV/R +T20
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
Study NCT00454337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF + EFV or LPV/R
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
Study NCT02351414 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty (EVOLUTION®)
Study NCT01144065 — intervention group
Intervention type: PROCEDURE
Intervention: Hair sampling for the measurement of cortisol and testosterone
Description: Hair sampling for the measurement of cortisol and testosterone
Study NCT01074268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study NCT01074268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
Study NCT01074268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
Study NCT01074268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
Study NCT04074941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Intervention include low sodium or usual sodium diet
Study NCT04074941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Intervention include low sodium or usual sodium diet
Study NCT00828568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% manufactured by Taro
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study NCT00828568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara - Imiquimod 5%
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study NCT03276533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study NCT03276533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study NCT04349787 — intervention group
Intervention type: OTHER
Intervention: Computer-aided diagnosis (CADx)
Description: Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
Study NCT04349787 — intervention group
Intervention type: OTHER
Intervention: BLI Adenoma Serrated International Classification (BASIC)
Description: Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
Study NCT03276533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine plus Dexmedetomidine
Description: Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study NCT04749810 — intervention group
Intervention type: DRUG
Intervention: Elizaria®
Description: Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
Study NCT04073693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acids (BRCA)
Description: They were with BRCA during the day apart of following the standard recommendations
Study NCT04073693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Branched chain amino acids (BRCA)
Description: They were with BRCA during the day apart of following the standard recommendations
Study NCT02930109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-200
Description: During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
Study NCT02930109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
Study NCT03398928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture added to usual care
Study NCT00736099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptine 5 mg
Description: safety and efficacy of linagliptine 5 mg open label
Study NCT00736099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptine 5 mg and pioglitazone 30 mg
Description: efficacy and safety of the combination linagliptine and pioglitazone
Study NCT02801851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREEN-ED
Description: SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
Study NCT03068910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
Study NCT03068910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Study NCT03068910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study NCT03068910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study NCT02605083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: Will be given orally once or twice daily. Each treatment cycle = 21 days.
Study NCT01695798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable polio vaccine and Bivalent oral polio vaccine
Description: One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone
Study NCT02814669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
Study NCT02814669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 Dichloride
Description: Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
Study NCT02887482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5700
Description: GLS 5700 at 2 mg DNA/dose
Study NCT02887482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01560091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silodosin
Description: 8mg PO Qday
Study NCT01560091 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extra-corporeal shock wave lithotripsy
Description: ESWL
Study NCT01560091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-corporeal shock wave lithotripsy
Description: ESWL
Study NCT01560091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg PO Qday
Study NCT02290028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sentus QP left ventricular lead
Description: Implantation of quadripolar left ventricular lead in patients with CRT-D indication
Study NCT02661282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Description: Given IV
Study NCT04069975 — intervention group
Intervention type: OTHER
Intervention: Sedation
Description: The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
Study NCT04153266 — intervention group
Intervention type: OTHER
Intervention: No intervention is planned for this study
Description: No intervention was/is planned for this study. The study is questionnaire-based (observational).
Study NCT01812707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening
Study NCT02661282 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Description: Given IV
Study NCT02661282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02661282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01812707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening
Study NCT03605745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Vapor Ablation
Description: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.
Study NCT02661282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02661282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT02661282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02661282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03918733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: surgical treatment will be done of failed root canal treated teeth
Study NCT03918733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical retreatment
Description: Non surgical retreatment will be done.
Study NCT02025023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil Injection
Description: If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
Study NCT02025023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: If chalazion present at follow-up, another Triamcinolone injection will be done.
Study NCT02025023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Curettage
Description: If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
Study NCT04349176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose
Description: Randomized to either 100U or 155U
Study NCT02122471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study NCT02122471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02082262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
Study NCT04463277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
Study NCT04463277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
Study NCT04463277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding with Calorie Restriction
Description: Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
Study NCT01293409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Brain-Targeted Bright Light Treatment
Description: Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
Study NCT02393079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (TCLT)
Description: Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
Study NCT01293409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Brain-Targeted Bright Light Treatment
Description: Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
Study NCT02980328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level light therapy
Description: we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study NCT02980328 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study NCT04438629 — intervention group
Intervention type: DRUG
Intervention: COVID-19 treatment
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.